Group 1 - The core business of the company is the research, development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has a range of products including the Columbus 3D cardiac electrophysiology mapping system and various disposable catheters and ablation devices [2] Group 2 - As of the latest financial report for Q1 2025, the company achieved a revenue of 104 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, up 328.63% [3] - The company's gross profit margin stands at 60.56% [3] - The company's current price-to-earnings (PE) ratio is 140.53, significantly higher than the industry average of 51.36 [3]

Core Viewpoint - The company, Microelectrophysiology, is leveraging capital to accelerate innovation and expand its market share in response to national procurement policies, aiming for a global market presence [1][2]. Group 1: Capital and Innovation - The successful listing on the Sci-Tech Innovation Board in August 2022 has provided strong development momentum for the company, allowing it to maintain strategic focus in high-investment, long-cycle innovation [1]. - The company plans to allocate nearly 25% of its revenue to R&D in 2024, positioning it as a leader in the industry [1]. - The capital injection has enhanced the company's resource integration capabilities, improving its supply chain management and international cooperation [2]. Group 2: Market Dynamics and Performance - From 2022 to 2024, the company's revenue is projected to grow from 260 million to 413 million, with net profit turning from a loss of 11.29 million to a profit of 5.08 million [2]. - The domestic electrophysiology device market is undergoing structural changes, with domestic companies like Microelectrophysiology increasing their market share against long-standing foreign competitors [2][3]. Group 3: Technological Advancements - The company has achieved a significant leap in technological capabilities, moving from a follower to a competitor on par with international giants in areas like three-dimensional mapping and magnetic electric positioning [3]. - The implementation of national procurement policies has accelerated the entry of products into clinical applications, enhancing the company's market reach [3]. Group 4: Global Expansion - The company is strategically focusing on the European market due to its large scale, strong insurance payment capabilities, and relatively fair competition environment [5]. - Emerging markets in Asia-Pacific, Latin America, and the Middle East are also targeted due to their high growth potential [5]. - The company acknowledges the challenges posed by complex market entry requirements and varying certification standards across different regions [5]. Group 5: Future Outlook - The company is optimistic about its international prospects, believing that advancements in technology and brand influence will enable it to capture a share of the global market [5]. - The dual pressures of international market expansion and intensified domestic competition are recognized, but the company is committed to continuous technological innovation and strengthening its entire industry chain [5].

Company Overview - Shanghai Microelectrophysiology Medical Technology Co., Ltd. focuses on innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment, aiming to provide globally competitive integrated solutions centered on precise interventional navigation [2] Product Portfolio - The main products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder 3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2] - The company’s cryoablation equipment and balloon-type cryoablation catheters have been approved for inclusion in the "2024 Shanghai Biomedical 'New Excellent Drugs and Devices' Product Directory" [2] - The fourth-generation 3D cardiac electrophysiology mapping system is also listed in the "2024 Shanghai Innovative Product Recommendation Directory" [2] Financial Performance - For Q1 2025, the company reported revenue of 104 million yuan, a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, reflecting a significant year-on-year growth of 328.63% [3] - The gross profit margin stands at 60.56% [3] Market Position - As of June 26, the company's stock closed at 19.68 yuan, with a rolling price-to-earnings (PE) ratio of 140.81, significantly higher than the industry average PE of 49.45 [1][3] - The total market capitalization is 9.261 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 7,764, a decrease of 209 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

证券代码：688351 证券简称：微电生理 公告编号：2025-012 上海微创电生理医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 18 日 | 1、出席会议的股东和代理人人数 | 85 | | --- | --- | | 普通股股东人数 | 85 | | 2、出席会议的股东所持有的表决权数量 | 371,096,329 | | 普通股股东所持有表决权数量 | 371,096,329 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.8559 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.8559 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1 本次会议召开及表决方式符合《中华人民共和国公司法》（以下简称《公司 法》）及《上海微创电生理医疗科技股份 ...

北京世辉律师事务所 关于上海微创电生理医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 致：上海微创电生理医疗科技股份有限公司 北京世辉律师事务所（以下简称"本所"）为具有从事法律业务资格的律师事 务所。本所接受上海微创电生理医疗科技股份有限公司（以下简称"公司"）的委 托，指派本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司股东会规则》等有关法律、法规、规范性文件 （以下统称"法律法规"）及《上海微创电生理医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的规定，就公司 2024 年年度股东大会（以下简称"本次 股东大会"）相关事宜出具本法律意见书。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承担相应法律责任。 为出具本法律意 ...

Core Viewpoint - The company, 微电生理, is experiencing a decline in stock price and has a high price-to-earnings (PE) ratio compared to the industry average, indicating potential overvaluation in the market [1][3]. Company Overview - 微电生理 specializes in the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2]. - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, focusing on precise interventional navigation [2]. Product Portfolio - Key products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2]. - The company’s cryoablation devices and balloon-type cryoablation catheters have been recognized in the 2024 Shanghai "New Excellent Drugs and Devices" product directory [2]. Financial Performance - In Q1 2025, the company reported revenue of 1.04 billion yuan, a year-on-year increase of 16.77%, and a net profit of 178.7 million yuan, reflecting a significant year-on-year growth of 328.63% [3]. - The gross profit margin for the company stands at 60.56% [3]. Market Position - As of June 10, the company's stock price closed at 19.47 yuan, with a rolling PE ratio of 139.31, significantly higher than the industry average of 51.00 and the median of 37.03 [1][3]. - The total market capitalization of 微电生理 is 9.163 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders is 7,764, a decrease of 209 from the previous count, with an average holding value of 352,800 yuan per shareholder [1].

微电生理 2024 年年度股东大会会议资料 证券代码：688351 证券简称：微电生理 上海微创电生理医疗科技股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 18 日 1 / 28 微电生理 2024 年年度股东大会会议资料 目 录 | 年年度股东大会会议须知 2024 | | | 3 | | | --- | --- | --- | --- | --- | | 2024 年年度股东大会会议议程 | 5 | | | | | 议案一：关于《2024 | 年度董事会工作报告》的议案 | | | 7 | | 议案二：关于《2024 | 年度监事会工作报告》的议案 | | | 12 | | 议案三：关于《2024 | 年度独立董事履职情况报告》的议案 | | | 16 | | 议案四：关于 2024 | 年年度报告及其摘要的议案 | | | 17 | | 议案五：关于《2024 | 年度财务决算报告》的议案 | | | 18 | | 议案六：关于 2024 | 年度利润分配预案的议案 | | | 24 | | 议案七：关于 2025 | 年度日常关联交易预计的议案 | | | 25 | | 议案八 ...

Group 1 - The company Shanghai MicroPort EP MedTech Co., Ltd. will hold its annual general meeting on June 18, 2025 [1][3] - The voting method for the meeting will combine on-site and online voting through the Shanghai Stock Exchange network voting system [1][3] - Shareholders must register for the meeting by the close of trading on June 10, 2025, to be eligible to attend [4][5] Group 2 - The meeting will take place at the company's office located at 588 Long 23, Tianxiong Road, Zhoupu Town, Pudong New District, Shanghai [4][5] - Shareholders can vote via the trading system from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on the day of the meeting [1][3] - The company has specified that related shareholders, such as MicroPort Investment Holdings Co., Ltd., should abstain from voting [3]

证券代码：688351 证券简称：微电生理 公告编号：2025-011 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 18 日 14 点 30 分 上海微创电生理医疗科技股份有限公司董事会 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 召开地点：上海市浦东新区周浦镇天雄路 588 弄 23 号楼 3 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 18 日 至2025 年 6 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年6月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 ...

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].